1. Scrip
  2. >>New Products

BeyondSpring's Next Move Uncertain After Plinabulin CRL

Limited Impact On China Partner Hengrui?

 
• By Brian Yang

Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.

Business uncertainty and risk showing a winding road high above the clouds showing the concept of danger and challenges faced in business and the corporate world of finance and financial services.
BEYONDSPRING'S PLINABULIN GETS US CRL, NEXT MOVE UNCERTAIN • Source: Alamy

On 1 December, Chinese biotech BeyondSpring Inc. said it had received a Complete Response Letter (CRL) from the US Food and Drug Administration, under which the agency refused to approve its drug plinabulin for chemotherapy-induced neutropenia due to results from the single Phase III registrational trial being “not sufficiently robust to demonstrate benefits" and meaning a second well-controlled trial will be required.

The small molecule treatment is designed for use in combination with granulocyte colony-stimulating factor (G-CSF) for cancer patients with reduced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.